





2nd East Anglian Glaucoma Microsurgery Symposium iGLEAMS 2023



Friday 12th May and Saturday 13th May 2023
Colchester, UK



iStent
inject® W



POWERFUL. PREDICTABLE. PROVEN

PROVEN PLATFORM

iStent *inject*® is the gold standard in Trabecular Micro-Bypass surgery, continuing the legacy of excellence set throughout 20 years of iStent® devices. It's backed by the most robust, diverse, and longest-term body of clinical evidence for any MIGS procedure available today, given through clinical rigor and integrity.

8 year study with iStent **demonstrated sustained protection against visual field loss**, as well as preservation of best corrected visual acuity, cup to disc ratio, and retinal nerve fiber layer thickness⁹

8

38

38 publications **demonstrate the power of iStent technologies to protect against visual field loss**[†]

PROTECTS
VISUAL FIELDS^{1,9}

PROVEN

LOW RATE OF
SECONDARY SURGERY
INTERVENTIONS^{4,5,10}

<0.01

<0.01 decibel mean change in visual field mean deviation from baseline at 24 months in iStent *inject*-treated eyes in a pivotal trial¹

2.6% of 778 patients in a **meta-analysis** of stand alone iStent *inject* eyes went on to require secondary incisional surgery during follow up⁵

2.6%

4% of 125 patients in **real world study** of stand alone and combined iStent *inject* cases required a secondary procedure during **5 years of follow up**⁴

4%

1%

Only 1% of 186 eyes in a **randomised controlled trial** went on to require secondary incisional surgery during **3 years follow up**¹⁰

LEGACY OF EXCELLENCE

20 Years of Data. 20K+ Eyes Studied. 20+ Countries.

Scientific evidence and clinical rigor have been at the heart of Glaukos, with the earliest publication on iStent® dating back to 2002 - years prior to the iStent® pivotal trial. Today, this same rigor and integrity is applied to our business as we remain focused on generating strong clinical evidence.



1. Samuelson, Thomas W, et al. "Prospective, randomized, controlled pivotal trial of an ab interno implanted trabecular micro-bypass in primary open-angle glaucoma and cataract: two-year results." *Ophthalmology* 126.6 (2019): 811-821. 4. Hengger, Fritz H., Gerd U. Auffarth, and Ina Conrad-Hengger. "iStent inject Trabecular Micro-Bypass with or Without Cataract Surgery Yields Sustained 5-Year Glaucoma Control." *Advances in Therapy* (2022): 1-15. 5. Healey, Paul R., et al. "Stand-alone iStent trabecular micro-bypass glaucoma surgery: A systematic review and meta-analysis." *Journal of Glaucoma* 30.7 (2021): 606-620. 9. Salimi, Ali, Harrison Watt, and Paul Harasymowicz. "Long-term outcomes of two first-generation trabecular micro-bypass stents (iStent) with phacoemulsification in primary open-angle glaucoma: eight-year results." *Eye and Vision* 8.1 (2021): 1-12. 10. Samuelson TW, on behalf of the iStent inject Pivotal Trial Study Team. "Three-Year Effectiveness and Safety of 2nd-Generation Trabecular Micro-Bypass (iStent inject)." Paper at the Annual Meeting of the American Academy of Ophthalmology (AAO), Virtual Meeting: November 13-15, 2020. 1. Data on file.

iStent inject® W IMPORTANT SAFETY INFORMATION

INDICATION FOR USE: The iStent inject W is intended to reduce intraocular pressure safely and effectively in patients diagnosed with primary open-angle glaucoma, pseudo-exfoliative glaucoma or pigmentary glaucoma. The iStent inject W can deliver two (2) stents on a single pass, through a single incision. The implant is designed to stent open a passage through the trabecular meshwork to allow for an increase in the facility of outflow and a subsequent reduction in intraocular pressure. The device is safe and effective when implanted in combination with cataract surgery in those subjects who require intraocular pressure reduction and/or would benefit from glaucoma medication reduction. The device may also be implanted in patients who continue to have elevated intraocular pressure despite prior treatment with glaucoma medications and conventional glaucoma surgery. CONTRAINDICATIONS: The iStent inject W System is contraindicated under the following circumstances or conditions: • In eyes with primary angle closure glaucoma, or secondary angle-closure glaucoma, including neovascular glaucoma, because the device would not be expected to work in such situations. • In patients with retrolental tumor, thyroid eye disease, Sturge-Weber Syndrome or any other type of condition that may cause elevated episcleral venous pressure. WARNINGS/ PRECAUTIONS: • For prescription use only. • This device has not been studied in patients with uveitic glaucoma. • Do not use the device if the Tyvek® lid has been opened or the packaging appears damaged. In such cases, the sterility of the device may be compromised. • Due to the sharpness of certain injector components (i.e. the insertion sleeve and trocar), care should be exercised to grasp the injector body. Dispose of device in a sharps container. • iStent inject W is MR-Conditional; see MRI Information below. • Physician training is required prior to use of the iStent inject W System. • Do not re-use the stent(s) or injector, as this may result in infection and/or intraocular inflammation, as well as occurrence of potential postoperative adverse events as shown below under "Potential Complications." • There are no known compatibility issues with the iStent inject W and other intraoperative devices. (e.g., viscoelastics) or glaucoma medications. • Unused product & packaging may be disposed of in accordance with facility procedures. Implanted medical devices and contaminated products must be disposed of as medical waste. • The surgeon should monitor the patient postoperatively for proper maintenance of intraocular pressure. If intraocular pressure is not adequately maintained after surgery, the surgeon should consider an appropriate treatment regimen to reduce intraocular pressure. • Patients should be informed that placement of the stents, without concomitant cataract surgery in phakic patients, can enhance the formation or progression of cataract. ADVERSE EVENTS: Please refer to Directions For Use for additional adverse event information. CAUTION: Please reference the Directions For Use labelling for a complete list of contraindications, warnings and adverse events.

© 2022 Glaukos Corporation. Glaukos, iStent inject® and iStent inject® W are registered trademarks of Glaukos Corporation. PM-EU-0163



Welcome

to the 2nd East Anglian Glaucoma Microsurgery Symposium

Dear Colleagues, highly esteemed delegates of iGLEAMS and all friends of modern glaucoma surgery,

A warm welcome to our second East Anglian Glaucoma Microsurgery Symposium, iGLEAMS, held at the ICENI Centre and Essex Business School of the University of Essex in Colchester, UK. As with previous years, this meeting remains a lively exchange of information, innovation and simulation on cutting-edge new technologies and state-of-the-art advancements in the ever-evolving armamentarium of minimally invasive glaucoma surgery, MiGS, MiBS and MiMS (with the latter coming soon to a theatre near you)!

The historic city of Colchester is officially Britain's first and oldest recorded town, originally a Roman city in 77 AD, which was granted City status by Queen Elizabeth II, just 3 days before her repose in 2022. We are extremely glad the Symposium is hosted by the world-renowned ICENI Centre, an exceptional 2-storey surgical simulation centre with outstanding facilities comprising seven latest model Leica surgical simulation microscopes, TriTeQ3 DRV 3D and NGENUITY 3D visualisation systems, EyeSi Virtual Reality stereo-simulation system, large variety of model eyes for artificial Glaucoma Simulation Surgery on MiGs, MiBS, MiMS, Tubes, Trabeculectomy, Aqueous Shunts and many more!

Friday 12th May 2023 is action-packed and full hands-on surgical simulation on 12 x MiGS in 3 different rooms with 3 x STEMI and 1 x DRV 3D each (12 stations) all at the dedicated ICENI Simulation Centre with skills to be taught and delivered by national and international experts, augmented by the pharmaceutical industry, to whom we are most grateful. We sincerely thank Glaukos, iSTAR Medical, Alcon, Sight Sciences, Haag Streit, Santen, Altomed, Kestrel Ophthalmics, Abbvie, Bausch & Lomb, Rheon Medical and Thea Pharmaceuticals for their generous contributions towards training and material support for the MiGS Dry Labs. We also thank our expert Surgical Trainers for their time and tireless efforts in medical education. Much appreciated!

Saturday 13th May is promising to be an unforgettable event with a stellar cast of eminent Speakers, all of whom are key opinion leaders in the field of micro-invasive glaucoma surgery. We would like to thank The Essex Business School for their kind hospitality in a unique and spacious venue with an outstanding lecture hall and exhibition facilities. 3D NGENUITY videos will be projected during the day, Slido interactive sessions will take place with audience voting, and, finally, three prestigious awards are to be won for best presentations at the conference. Prof Sheng Lim, Prof Tarek Shaarawy, Prof André Mermoud with fellow Leandro Oliverio, Mr Imran Masood, Mr Dan Lindfield, Mr Andrew Tatham, Mr Gok Ratnarajan, Mr Ian Rodrigues, all have prepared fascinating presentations of various MiGS topics. Guest star Mr Lukan Mishev, the pan-European NGENUITY master, will teach us some of his little tips and tricks on optimisation of 3D visualisation systems with polychromatic filters. Magical!

Once again, on behalf of the iGLEAMS Organising Committee, may I extend a warm welcome to The ICENI Centre, Colchester, Essex UK, for what promises to be a richly educational as well as profoundly entertaining MiGS Symposium. Thank you for joining us and please do enjoy the ride!

With warmest wishes,



Chrys Dimitriou
Glaucoma Lead for ESNEFT
East Anglia Deanery Simulation Lead
Founder, Chair & Organiser of iGLEAMS, Colchester, Essex UK



Committee Members

Mr Anthimos Vlavianos
Consultant Ophthalmic Surgeon
East Suffolk & North Essex NHS Foundation Trust

Ms Penny O'Toole
ICENI Centre Business and Curriculum Manager

Mr Edward Horseman
ICENI Centre Technician

Ms. Sally Foster
ICENI Centre Content Producer

Event Essex
University of Essex

MINject®



Bio-integrating, supraciliary MIGS

Visit our booth!

Soft,
flexible,
conforming

Biointegrates
with surrounding
tissue minimising
fibrosis¹

Silicone
matrix



CE
2797

MJ13-COMEU-CongAdA4-20230316

¹ Grierson I, Minckler D, Rippey M.K. et al. "A novel suprachoroidal microinvasive glaucoma implant: in vivo biocompatibility and biointegration." *BMC biomed eng* 2, 10 (2020).

MIGS: minimally-invasive glaucoma surgery.

MINject® is indicated in adult patients diagnosed with open angle glaucoma. Please see Instructions for Use for complete product information: www.istarmed.com. MINject® is a registered trademark in the European Union.

 **ISTAR**
MEDICAL

MINject@istar-medical.com

Speakers

Mr. Chrys Dimitriou

Glaucoma Lead
East Suffolk & North Essex
Foundation Trust



Mr Chrysostomos Dimitriou has a passion for MiGS including MINject, XEN45, iStent, Hydrus, Omni, iTRACK, Preserflo and others. Mr Dimitriou has implanted the highest number of MINjects in the world to date. He is the current Glaucoma Lead for ESNEFT and holds Level 2 Clinical Excellence Award since 2019. Mr Dimitriou serves as Principal Investigator for several glaucoma trials. Mr Dimitriou has established the ICENI International Fellowship programme for training in complex cataract and modern glaucoma surgery. He chairs the annual iGLEAMS MiGS Conference of East Anglia, which he founded in 2022, pioneering ophthalmic simulation, surgical innovation and medical education.

Professor Kin Sheng Lim

Founder/Director of King's
College London Frost Eye
Research Department
St. Thomas' Hospital, London



Professor Kin Sheng Lim is an internationally renowned ophthalmologist and founder of the Kings College London Frost Eye Research Department at St. Thomas Hospital. Professor Lim is one of the world's leading experts on glaucoma and pioneer in many glaucoma surgeries such as Baerveldt implant, EyeWatch, Paul implant, PreserFlo, SLT laser, amongst many others. He has delivered over 200 lectures nationally and internationally and has authored over 100 publications. He has been involved as chief or principal investigator in many important glaucoma research trials to date.

Mr. Daniel Lindfield

Glaucoma Lead
The Royal Surrey County
Hospital (RSCH)



Mr Dan Lindfield is a multi-award-winning consultant ophthalmologist and eye surgeon in Guildford and Farnham who specialises in cataracts and glaucoma. Mr Lindfield has been twice ranked amongst the world's top 100 surgeons. He has an extensive portfolio of research and academic work which is published in leading peer-reviewed journals. Mr Lindfield is the Training Programme Director for Ophthalmology across Kent, Surrey and Sussex UK.

Mr. Imran Masood

Glaucoma Lead
Birmingham & Midland
Eye Centre



Mr Imran Masood is a highly skilled consultant ophthalmic surgeon in Birmingham, specialising in complex cataract surgery and complex glaucoma surgery, and is a national leader in minimally invasive glaucoma surgery. He has completed more successful iStent implant procedures in complex glaucoma patients than any other doctor in the UK. Mr Masood trained at the prestigious Moorfields Eye Hospital in London and is the current director of both the Glaucoma Service at the Birmingham and Midland Eye Centre and the Birmingham Institute of Glaucoma Research. He also holds the positions of Honorary Senior Clinical Lecturer and Honorary Consultant Ophthalmologist at the University of Birmingham UK.

Speaking on behalf
of Prof André Mermoud

Leandro Oliverio
Chef de Clinique Spécialiste
FMH en Ophtalmologie



Professor André Mermoud

is FMH-certified ophthalmologist and ophthalmic surgeon. Dr Mermoud is Professor of Ophthalmology at Hôpital Ophtalmique Jules Gonin, University of Lausanne and an active Researcher in developing new surgical techniques for glaucoma and cataract surgery. He is author and co-author of multiple publications in the field of minimally invasive glaucoma surgery.



Mr. Lukan Mishev

Head of Glaucoma
Focus Eye Centre, Sofia



Mr Lukan Mishev from Bulgaria is a master surgeon who often livestreams his cases to a worldwide audience. Dr. Mishev is a world renowned vitreo-retinal, glaucoma and cataract surgeon with a special interest in 3D stereoscopic imaging for anterior and posterior segment operations. Dr. Mishev is the Head of Focus Eye Centre in Sofia and a prolific researcher and innovator.

Mr. Gokulan Ratnarajan

Director of Glaucoma Services
Queen Victoria Hospital



Mr Gokulan Ratnarajan is a Consultant Glaucoma and Anterior Segment Surgeon at the prestigious Eye Unit and Eye Bank at Queen Victoria, East Grinstead, where he leads the Glaucoma Unit and runs a fellowship programme. He is the founder and

director of Innovation Eye Clinic, which aims to provide world-class, local and affordable private health care. Mr Ratnarajan enjoys working closely with motivated, like-minded optometrists to help deliver exceptional care.

Mr. Ian Rodrigues

Consultant Ophthalmic
Surgeon in Glaucoma
Guys & St. Thomas' NHS
Foundation Trust, London



Mr Ian Rodrigues is a consultant ophthalmologist sub-specialising in glaucoma. He was member of the 2022 NICE Glaucoma Guideline committee. He teaches on the Royal College of Ophthalmologists Microsurgical Skills Courses and examines for the Royal College of Physicians and Surgeons of Glasgow. His other interests include digital healthcare and research in surgical glaucoma treatment.

Professor Tarek Shaarawy

Head of Glaucoma Unit &
Glaucoma Research Group
University of Geneva Hospitals,
Geneva



Professor Tarek M. Shaarawy is the Head of the Glaucoma unit, and the Glaucoma surgery research group at the University of Geneva Hospitals. He is currently the President of the International Society of Glaucoma surgery as well as the associate vice president of the World Glaucoma Association. He is the author and editor of five textbooks on Glaucoma, and more than 100 book chapters and publications in peer reviewed journals, many of which have Prof Shaarawy on their editorial board. Prof Shaarawy is an active member of a number of NGOs dealing with global prevention of blindness.

Mr. Andrew Tatham

Consultant
Ophthalmic Surgeon
Princess Alexandra Eye Pavilion,
Edinburgh



Dr Tatham is a consultant ophthalmic surgeon at Princess Alexandra Eye Pavilion and a specialist in cataract and glaucoma surgery. He has 15 years' experience in ophthalmology and was trained at two of the world's leading eye hospitals - Moorfields Eye Hospital, London and Shiley Eye Institute, University of California San Diego, USA. He was ranked first in Europe in the 2011 European Board of Ophthalmology examination and has received research awards from Royal College of Ophthalmologists, UK and Eire Glaucoma Society. In 2015, he was the only UK ophthalmologist to receive an innovative research award from the Association for Research in Vision and Ophthalmology (ARVO).

Thank you sponsors and exhibitors

The following companies have agreed sponsorship of this event and have had no input into the agenda or content of the meeting.



Platinum sponsor - Glaukos

Glaukos is an ophthalmic medical technology and pharmaceutical company focused on developing and commercializing novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases. We first developed Micro-Invasive Glaucoma Surgery (MIGS) as an alternative to the traditional glaucoma treatment paradigm, launching our first MIGS device commercially in 2012, and have since developed a portfolio of technologically distinct and leverageable platforms to support ongoing pharmaceutical and medical device innovations.



Gold sponsor - iSTAR Medical

iSTAR Medical is a medtech company developing MINject®, a revolutionary microinvasive glaucoma surgery (MIGS) device for patients with primary open-angle glaucoma. MINject uses the innovative STAR® material, a soft and flexible, medical-grade silicone with a microporous, multi-channel geometry to provide an effective solution to safely reduce intraocular pressure (IOP). iSTAR Medical was founded in 2011 and is headquartered in Belgium.



Gold sponsor - Alcon

Alcon is the global leader in eye care, dedicated to helping people see brilliantly. With our 70-plus-year heritage, we are the largest eye care device company in the world - with complimentary businesses in Surgical and Vision Care.



Silver sponsor - Santen

At Santen, ophthalmology is our singular focus. We explore new possibilities in eye care and work with clinicians to support you in bringing happiness and hope to people with eye disease. Visit us at this meeting to discuss the lives of patients with severe dry eye disease, VKC and glaucoma.



Silver sponsor - Sight Sciences

Sight Sciences is an eyecare technology company focused on innovative solutions intended to transform care and improve patients' lives. The company's portfolio, featuring the OMNI® Surgical System and the in-office TearCare® System, uses minimally invasive or non-invasive approaches to target the underlying causes of the world's most prevalent eye diseases.



Silver sponsor - Kestrel Ophthalmics

Kestrel Ophthalmics, part of the Cutting Edge group, a French manufacturing organisation supplying a range of standard/premium IOL's. Kestrel is also the exclusive UK distributor for the Trabex™+ Glaucoma device used for 'Irrigating Goniotomy™'. Trabex™+ offers complete Trabecular Meshwork excision, optimal design for angle anatomy and enhanced control of the anterior chamber.



Bronze sponsor - AbbVie

People. Passion. Possibilities.®

We're a company that takes on the toughest health challenges. But we do more than treat diseases—we aim to make a remarkable impact on people's lives. Since our launch in 2013, we have invested ~\$50 billion in research to discover, develop and deliver new medicines. We target diseases with significant unmet need where we can improve the standard of care with innovative new therapies. We're constantly working to create solutions that go beyond treating the illness to have a positive impact on patients' lives, on societies - and on science itself.

Our mission is to discover and deliver innovative medicines and products that solve serious health issues and enhance people's lives today and address the medical challenges of tomorrow.



Bronze sponsor - Altomed

Altomed are delighted to support the 2nd East Anglian Glaucoma Micro-Surgery Symposium. We hope you get to experience the simplicity and efficiency of the enhanced KDB Glide for excisional goniotomy which forms part of the New World Medical family of Ahmed Glaucoma Valves and ClearPath Glaucoma Drainage Implants™.



Bronze sponsor - Bausch & Lomb

Bausch and Lomb work with MIMS®, which is a stent-less, simple (short learning curve, no surgical goniotomy required), rapid (average time 2 minutes 3 seconds (+43 seconds)) glaucoma surgical treatment designed to effectively lower IOP without invasive surgery and without leaving an implant in the eye. MIMS® is a trademark of Sanoculis Ltd and legal manufacturer



Bronze sponsor - Haag-Streit UK

Haag-Streit UK is a leading UK provider of diagnostic and surgical equipment for ophthalmologists. It provides a comprehensive portfolio of gold-standard micro-surgical instruments and procedures & implants. HS-UK's portfolio includes the newly-launched iTrack™ Advance surgical system, a next generation canaloplasty device for glaucoma. The iTrack Advance offers an easy-to-use handheld injector, combining viscodilation and catheterisation. The innovative design offers an illuminated canaloplasty performed over 360° of the outflow pathway via a single intubation. www.haagstreituk.com.



Bronze sponsor - Rheon

Rheon Medical has developed the eyeWatch technology, the world's first adjustable shunt for the surgical treatment of glaucoma. The eyeWatch has been tested clinically in more than 400 patients and has delivered outstanding results in terms of pressure control and post-operative complications.



Bronze sponsor - Théa

For the last 150 years, Théa have been pioneers in ophthalmology. By developing treatments, providing information, and sharing knowledge with specialists around the world, we enable everyone to keep their eyes wide open. Théa specialise in preservative-free treatment at accessible prices, addressing the established position that preservative-free is more expensive than preserved eye care and ensuring that patients have access to a range of efficacious, preservative-free treatments. As part of Europe's leading independent ophthalmic pharmaceutical company, Laboratoires Théa, we are dedicated exclusively to ophthalmology and offer an extensive portfolio of pharmaceutical-grade, innovative products in multiple therapy areas including glaucoma, cataract, dry eye, infection, and inflammation.

Friday 12 May 2023

MiGS Course - Dry Labs

Venue: ICENI Centre, Colchester

Morning Session - East Anglian Deanery Trainees

Time	Topic	
8.45am - 9.15am	Registration and Reception Refreshments	
9.15am - 9.30am	Welcome & Introductions	
9.30am - 11.30am	Lecture Hall x 12 Presentations (10 mins each video-lecture)	Group 1
9.30am - 11.30am	Dry Lab STEMi x 12 Implants/Devices	Group 2
11.30am - 12.00pm	Refreshment Break	
12.00pm - 2.00pm	Lecture Hall x 12 Presentations (10 mins each video-lecture)	Group 2
12.00pm - 2.00pm	Dry Lab STEMi x 12 Implants/Devices	Group 1
2.00pm	Closing Remarks and Lunch	

MiGS Course - Dry Labs

Venue: ICENI Centre, Colchester

Afternoon Session - Non EoE Deanery Trainees

Time	Topic	
2.00pm - 2.30pm	Registration and Reception Refreshments	
2.30pm - 2.45pm	Welcome & Introductions	
2.45pm - 4.45pm	Lecture Hall x 12 Presentations (10 mins each video-lecture)	Group 1
2.45pm - 4.45pm	Dry Lab STEMi x 12 Implants/Devices	Group 2
4.45pm - 5.00pm	Refreshment Break	
5.00pm - 7.00pm	Lecture Hall x 12 Presentations (10 mins each video-lecture)	Group 2
5.00pm - 7.00pm	Dry Lab STEMi x 12 Implants/Devices	Group 1
7.00pm	Closing Remarks	



- STEMi 1 = **ISTENT** - 2 x OST
- STEMi 2 = **MINIject** - 2 x OST
- STEMi 3 = **XEN-45** - 2 x OST
- STEMi 4 = **PRESERFLO** - 2 x OST
- STEMi 5 = **OMNI** - 2 x OST
- STEMi 6 = **Kahook DB** - 2 x OST
- STEMi 7 = **EyeWatch** - 2 x OST
- STEMi 8 = **Endo Optiks** - 2 x OST
- STEMi 9 = **HYDRUS** 2 x OST
- STEMi 10 = **Trabex+** 2 x OST
- STEMi 11 = **iTRACK** 2 x OST
- STEMi 12 = **MiMS** 2 x OST

IRRIGATING GONIECTOMY™

A NEW ANGLE IN
GLAUCOMA
MANAGEMENT

TrabEx+™

- ∅ I/A
Maintains
a Deep,
Stable and
Clear A/C
- ∅ Smooth
Trabecular
Meshwork
excision
- ∅ Optimal
Design for
angle anatomy
- ∅ Can be used with
any phaco machine



Saturday 13 May 2023 - iGLEAMS

2nd International Glaucoma Microsurgery Symposium, East Anglia

Venue: Essex Business School, University of Essex

Time	Topic	Speakers
8.30am - 9.00am	Registration	
9.00am - 9.15am	Welcome & Introductions from ESNEFT, Research & Innovation, and Clinical Decision Group Leadership Team	Mr. Shane Gordon Mr. Scott Stavri Mr. Jignesh Patel Mr. Chrys Dimitriou
9.15am - 9.45am	ECP - The most versatile MIGS?	Mr. Ian Rodrigues
9.45am - 10.15am	Combining MiGS, MiBS et al - Personalised Medicine in Action	Mr. Gok Ratnarajan
10.15am - 10.45am	The Hamlet of MiGS: Trabeculotomy/Goniotomy Tear or Spare? That is the Question	Prof. Andre Mermoud Mr. Leandro Oliverio
10.45am - 11.15am	The Art of Trabecular Bypass & Trabeculostomies Primum Non Nocere - Less is More	Mr. Dan Lindfield
11.15am - 11.30am	Refreshment Break	Presentation by Alcon
11.30am - 12.00pm	The Closest you can get to Trabeculectomy PRESERFLO: Are we there yet?	Prof. Tarek Shaarawy
12.00pm - 12.30pm	EyePlate & EyeWatch: State-of-the-Art Flow-Control Systems: Watch this Space!	Prof. Kin Sheng Lim
12.30pm - 1.00pm	Demystifying the NGENUITY 3D Visualisation System for Anterior Segment Surgery: A Magical Insight Take it from the Expert	Mr. Lukan Mishev
1.00pm - 2.00pm	LUNCH	Presentation by Glaukos
2.00pm - 2.30pm	Harnessing the Power of Evidence-based Medicine HYDRUS - Scaffolding the Canal of Schlemm	Mr. Andrew Tatham
2.30pm - 3.00pm	Strengths & Limitations of Schlemm's Canaloplasty in the Current Glaucoma Surgery Landscape	Mr. Imran Masood
3.00pm - 3.15pm	Refreshment Break	Presentation by iSTAR Medical
3.15pm - 3.45pm	Welcome to the Future of Ab Interno Glaucoma Surgery! Suprachoroidal Space Odyssey & MINInject: My Journey so far	Mr. Chrys Dimitriou
3.45pm - 4.00pm	Closing Remarks	
	Votes for Best Presentation Honorary Awards of the Colchester Eye Centre of Excellence	Kindly sponsored by Glaukos Platinum Sponsor for iGLEAMS 2023



Predictable and consistent outcomes now in your hands¹⁻³

The PRESERFLO[®] MicroShunt glaucoma drainage system is intended for reduction of intraocular pressure in eyes of patients with primary open-angle glaucoma where IOP remains uncontrollable while on maximum tolerated medical therapy and/or where glaucoma progression warrants surgery. Please read the PRESERFLO[®] MicroShunt Instructions for Use carefully before using the device. Date of preparation: February 2022 PP-PMS-EMEA-0302




One MIGS device. Two implant-free procedures. Three points of resistance.



Effectively target all three points of resistance with the OMNI[®] Surgical System to lower IOP in patients with Open-Angle Glaucoma.

- Trabecular Meshwork
- Schlemm's Canal
- Collector Channels



IMPORTANT PRODUCT INFORMATION

INDICATIONS FOR USE: The OMNI[®] Surgical System is indicated for the catheterization and transillumination viscodilation of Schlemm's canal and the cutting of trabecular meshwork to reduce intraocular pressure in adult patients with open-angle glaucoma.

CONTRAINDICATIONS: Do not use the OMNI[®] in any situations where the angle is compromised or has been damaged (e.g., from trauma or surgery); since it may not be possible to visualize the angle or to properly pass the microcatheter. Do not use the OMNI[®] in patients with angle recession; neovascular glaucoma; chronic angle closure; narrow-angle glaucoma; traumatic or malignant glaucoma; or narrow inlet canals with plateau iris.

Please refer to the full Instructions For Use, available at OMNISurgical.com/international, for warnings, precautions, and adverse event information.

©2022 Sight Sciences, Inc. Sight Sciences, the Sight Sciences logo, OMNI, and the OMNI logo are registered marks for Sight Sciences.

10/22 CE2797 OM-2602-0US-V1

ICENI Fellowship in Glaucoma & Complex Cataract Surgery

Main area	Ophthalmology	Town	Colchester
Contract	Fixed term: 12 months	Salary	£51,017 per annum
Hours	Full time - 40 hours per week	Salary period	Yearly
Job ref	432-MC2130	Closing	22/05/2023 23:59
Site	Colchester Hospital		

We are the largest NHS organisation in East Anglia. Our scale provides exciting opportunities for development, innovation, research, education and training.

Job Overview

Applications are invited for 2 full-time ICENI Centre International Fellowships with special interest in Glaucoma and Cataract surgery to join our dynamic team of 7 Consultants, 1 Associate Specialist, 3 Staff Grade Specialty Doctors, 1 Anterior Segment Fellow, 1 Retinal Fellow, and 4 Ophthalmic East Anglia Deanery Specialist Trainees (1 x TSC/ASTO/L4 Glaucoma), who are committed to providing the very highest standards of care. The state-of-the-art Colchester Eye Centre is located near the Colchester General University Hospital. The current Glaucoma Consultants provide all aspects of modern medical, laser and surgical therapy for glaucoma, including Selective Laser Trabeculoplasty with Ellex Tango, Micropulse Laser P3 + G6, expanding portfolio of MIGS (MINIject, HYDRUS, OMNi, iTRACK, XEN45, iStent G2 inject, Kahook ab interno trabeculotomy, TRABEX+), MSSS Trabeculectomy and EyeWatch, EyePlate, Baerveldt, Molteno, ClearPath and Paul Glaucoma Implant surgery. The Ophthalmic Day Care Unit is purpose-built for the exclusive use of the eye department and hosts 2 Theatre Suites with Leica Proveo 8 ophthalmic operating microscopes and Keeler Symphony digital video-slit-lamp.

The Glaucoma Unit holds an active Research Portfolio including the International Multi-Centre Study: "iSTAR Medical STAR VI Study", "STAR LIFE Registry Study for MINIject Suprachoroidal Implants", "Allergan-1924-701-007, A Prospective, Multicentre Clinical Trial for XEN45 Glaucoma Treatment System in Patients with Angle Closure Glaucoma", "Allergan TRITON Study on Slow Release Bimatoprost implant" and the National POEM Study in collaboration with East Anglia Deanery and Eastern NIHR LCRN. Good Clinical Practice (GCP) Certification is required for this post.

East Suffolk and North Essex NHS Foundation Trust is one of the largest NHS organisations in the country, employing over 10,000 staff and serving a population of almost 800,000 residents. Colchester offers all the advantages of urban living with easy access to the beautiful counties of Essex and Suffolk. Reasonable house prices, strategic location and an excellent choice of both state and private sector schools make this an ideal area for

families. There are numerous villages within easy driving distance from the hospital for those who prefer a rural setting, including the world-renown Constable Country and Flatford in East Bergholt. Colchester is linked to Cambridge, Chelmsford, Ipswich, Norwich and all big towns and cities of the United Kingdom by dual carriageways. London is easily accessible by rail in less than an hour. London Stansted airport is just over half-an-hour drive away.

The ICENI Centre

The ICENI Centre is a purpose-built medical education, simulation and training centre based at Colchester Hospital. The Centre delivers training both on-site and remotely using state of the art augmented and virtual reality simulation equipment in robotic surgery, laparoscopy, hysteroscopy, endovascular, ophthalmology and endoscopy. Our educational portfolio also includes courses using cadaveric and animal tissue, live surgery events and online events for thousands of learners. The East Anglian Simulation and Training Centre, based at Ipswich Hospital, has a suite of simulation rooms providing multidisciplinary healthcare education using high fidelity patient manikins and a clinical skills lab for wet tissue courses. The ICENI International Fellow will have access to The ICENI Centre Skills Lab, VR & AR simulation equipment including NGENUITY 3D VISUALISATION SYSTEM, STEMi ophthalmic simulation microscopes, EyeSi VR simulator, and experienced, supportive Clinical Mentors. The Fellowship post includes a dedicated session allocated to simulation activities, organising courses and masterclasses, including an international MiGS conference, and support training on model eyes and EyeSi virtual reality simulation for cataract and glaucoma surgery within the ICENI Surgical Simulation Centre.

For departmental visits and informal discussions, please contact Mr Chrys Dimitriou, Consultant Ophthalmic Surgeon and Glaucoma Lead, on tel.: +44 (0) 1206 7460 66, Penny O'Toole, Business and Curriculum Development Manager at Colchester ICENI Centre, on tel.: + 44 (0) 1206 7460 07 or Amy Sinclair, Fellowship and International Training Officer at Colchester ICENI Centre, on tel.: + 44 (0) 1206 7460 46.

Clinical leads & Educational / Clinical supervisors may include:



Chrys Dimitriou MBChB (Hons) · FRCOphth (Lond) · FEBOphth (Paris) · FEBOS (Glaucoma) · PGCertMedEd (Healthcare)
Mr Dimitriou is the Glaucoma Lead at the CECE and an active RCOphth College Tutor with keen interest in Education. He started the ASTO/TSC Glaucoma Fellowship programme. He specialises in all aspects of modern glaucoma surgery and lasers, with particular interest in MIGS devices, aqueous shunts, trabeculectomy and complex cataract surgery. He is a proficient high-volume cataract surgeon. In 2019, he humbly received Level 2 Clinical Excellence Award for services in Ophthalmology by the Trust.



Anthimos Vlavianos
Consultant Ophthalmic Surgeon for East Suffolk and North Essex Foundation Trust
Mr Anthimos Vlavianos is currently working as a Glaucoma Consultant at Ipswich Hospital, Ipswich, Suffolk, UK. He is offering the full spectrum of Glaucoma surgery (MIGS, trabeculectomy and aqueous shunts) as well as complex cataract surgery. He is fellowship-trained in Glaucoma and Cataract Surgery at Moorfields Eye Hospital, King's College Hospital and Royal Free Hospital in London.

